Published in Expert Opin Ther Targets on January 20, 2015
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res (2014) 0.84
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget (2015) 0.82
Immunotherapy of Childhood Sarcomas. Front Oncol (2015) 0.81
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.81
Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. J Mater Chem B Mater Biol Med (2015) 0.77
An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. PLoS One (2016) 0.77
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunol Res (2016) 0.76
Chimeric antigen receptor T cells therapy for tumor immunotherapy. Biosci Rep (2017) 0.75
Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. PLoS One (2016) 0.75
Lipid glycosylation: a primer for histochemists and cell biologists. Histochem Cell Biol (2016) 0.75
Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8(+) T cells. Sci Rep (2017) 0.75
Primary Leiomyosarcoma of the Pancreas-a Case Report and a Comprehensive Review. J Gastrointest Cancer (2016) 0.75
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. Oncol Ther (2016) 0.75
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. Oncoimmunology (2016) 0.75
PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging (2017) 0.75
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell (2017) 0.75
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol (2004) 2.06
Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol (2003) 2.05
Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol (2004) 2.00
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer (2006) 1.89
Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia (2005) 1.75
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol (2009) 1.61
Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan. Leuk Res (2005) 1.59
Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients. Pediatr Blood Cancer (2006) 1.55
Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer (2005) 1.53
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res (2009) 1.50
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer (2009) 1.49
Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatr Blood Cancer (2005) 1.45
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res (2010) 1.43
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. Pediatr Blood Cancer (2008) 1.43
Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy. J Pediatr Hematol Oncol (2003) 1.43
Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification. Med Pediatr Oncol (2003) 1.41
Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol (2003) 1.40
Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest (2007) 1.40
Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma. Pediatr Blood Cancer (2010) 1.39
Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev (2010) 1.38
EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res (2005) 1.37
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol (2006) 1.31
Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res (2003) 1.24
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol (2009) 1.23
The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg (2004) 1.20
Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res (2008) 1.17
Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res (2005) 1.16
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol (2007) 1.14
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med (2004) 1.06
Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer (2010) 1.03
A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin Cancer Res (2012) 1.02
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2011) 0.99
Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol (2003) 0.98
Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res (2007) 0.98
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J (2011) 0.98
Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6. Proc Natl Acad Sci U S A (2002) 0.96
In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res (2004) 0.95
Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer (2012) 0.95
Chronic neuroblastoma. Cancer (2002) 0.95
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer (2007) 0.94
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol (2003) 0.94
Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm (2005) 0.94
Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Genes Chromosomes Cancer (2013) 0.93
Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol (2004) 0.93
Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn (2007) 0.93
Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer (2010) 0.92
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res (2004) 0.92
Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma. Int J Cancer (2011) 0.91
Neuroblastoma--from genetic profiles to clinical challenge. N Engl J Med (2005) 0.91
Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer (2009) 0.91
Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs. Int J Cancer (2009) 0.90
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol (2011) 0.90
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res (2004) 0.89
Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody. J Immunol (2009) 0.89
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer (2014) 0.89
Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. Int J Cancer (2006) 0.89
Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography. J Clin Oncol (2008) 0.89
Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res (2014) 0.88
In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS One (2013) 0.88
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. J Pediatr Surg (2010) 0.87
Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol (2002) 0.86
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer (2014) 0.86
Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Med Genomics (2008) 0.86
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer (2008) 0.85
Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res (2014) 0.85
Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9. Neurosurgery (2008) 0.85
Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Res (2002) 0.85
Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther (2009) 0.84
Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatr Blood Cancer (2011) 0.84
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood (2008) 0.84
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol (2003) 0.84
A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases. J Nucl Med (2009) 0.83
Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett (2003) 0.83
Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer (2005) 0.82
Lack of early bevacizumab-related skeletal radiographic changes in children with neuroblastoma. Pediatr Blood Cancer (2009) 0.82
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer (2011) 0.82
Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. Cancer (2002) 0.82
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. Eur J Cancer (2010) 0.81
Neuroblastoma--linking a common allele to a rare disease. N Engl J Med (2008) 0.80
Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis. Genes Chromosomes Cancer (2014) 0.80
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology (2013) 0.80
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys (2010) 0.80
Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer (2002) 0.80
Management and outcome of stage 3 neuroblastoma. Eur J Cancer (2008) 0.79
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol (2003) 0.79
Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis. Cancer (2004) 0.79
Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma. Genes Chromosomes Cancer (2007) 0.79
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer (2012) 0.78
Brain-sparing radiotherapy for neuroblastoma skull metastases. Pediatr Blood Cancer (2008) 0.78
Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation. J Pediatr Hematol Oncol (2004) 0.78
Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg (2011) 0.78
Treatment of spinal involvement in neuroblastoma patients. Pediatr Neurosurg (2003) 0.78
What factors predict a favorable outcome in young children with disseminated neuroblastoma? Nat Clin Pract Oncol (2006) 0.77
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer (2013) 0.77
Reply to L. Moreno et al. J Clin Oncol (2013) 0.77